Tags

Type your tag names separated by a space and hit enter

Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex.
Behav Brain Res. 2020 Sep 01; 393:112769.BB

Abstract

According to preclinical and clinical studies, the antidepressant-induced increase in the activity of atypical antipsychotics may efficiently improve the treatment of negative and some cognitive symptoms of schizophrenia. In the present study, we aimed to evaluate the effects of the antidepressants escitalopram and mirtazapine and the atypical antipsychotic drug aripiprazole, administered separately or in combination, on the MK-801-induced deficits in the recognition memory test and on the extracellular levels of monoamines and their metabolites in the rat frontal cortex. Based on the results of the behavioral tests, co-treatment with an ineffective dose of aripiprazole (0.1 mg/kg) and escitalopram (2.5 and 5 mg/kg) or mirtazapine (5 mg/kg) abolished the deficits evoked by MK-801 in the novel object recognition test, and those effects were blocked by the 5-HT1A receptor antagonist (WAY 100,635) or the dopamine D1 receptor antagonist (SCH 23,390). Moreover, co-treatment with aripiprazole (0.3 mg/kg) and escitalopram (5 mg/kg) significantly increased the levels of noradrenaline and serotonin, decreased the level of its metabolite, and did not alter level of dopamine, but decreased the levels of its metabolites. In addition, co-treatment with aripiprazole (0.3 mg/kg) and mirtazapine (10 mg/kg) significantly increased the level of noradrenaline, did not change the levels of dopamine and serotonin, but increased the levels of their metabolites. Based on these results, the increase in the extracellular levels of noradrenaline or serotonin in the cortex induced by co-treatment with an antidepressant and aripiprazole may be very important for the pharmacotherapy of negative and some cognitive symptoms of schizophrenia.

Authors+Show Affiliations

Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Pharmacology, 12 Smętna Street, Kraków, Poland.Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Pharmacology, 12 Smętna Street, Kraków, Poland.Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Neurochemistry, 12 Smętna Street, Kraków, Poland.Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Neurochemistry, 12 Smętna Street, Kraków, Poland.Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Neuropsychopharmacology, 12 Smętna Street, Kraków, Poland.Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Pharmacology, 12 Smętna Street, Kraków, Poland; The Podhale State Higher Vocational School, Institute of Health Sciences, Faculty of Cosmetology,71 Kokoszków, Nowy Targ, Poland. Electronic address: rogoz@if-pan.krakow.pl.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32535184

Citation

Hereta, Marta, et al. "Effect of Combined Treatment With Aripiprazole and Antidepressants On the MK-801-induced Deficits in Recognition Memory in Novel Recognition Test and On the Release of Monoamines in the Rat Frontal Cortex." Behavioural Brain Research, vol. 393, 2020, p. 112769.
Hereta M, Kamińska K, Białoń M, et al. Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex. Behav Brain Res. 2020;393:112769.
Hereta, M., Kamińska, K., Białoń, M., Wąsik, A., Lorenc-Koci, E., & Rogóż, Z. (2020). Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex. Behavioural Brain Research, 393, 112769. https://doi.org/10.1016/j.bbr.2020.112769
Hereta M, et al. Effect of Combined Treatment With Aripiprazole and Antidepressants On the MK-801-induced Deficits in Recognition Memory in Novel Recognition Test and On the Release of Monoamines in the Rat Frontal Cortex. Behav Brain Res. 2020 Sep 1;393:112769. PubMed PMID: 32535184.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex. AU - Hereta,Marta, AU - Kamińska,Kinga, AU - Białoń,Magdalena, AU - Wąsik,Agnieszka, AU - Lorenc-Koci,Elżbieta, AU - Rogóż,Zofia, Y1 - 2020/06/11/ PY - 2019/12/16/received PY - 2020/03/11/revised PY - 2020/05/13/accepted PY - 2020/6/15/pubmed PY - 2020/6/15/medline PY - 2020/6/15/entrez KW - Antidepressants KW - Aripiprazole KW - Microdialysis KW - Novel object recognition test KW - Rats KW - Schizophrenia SP - 112769 EP - 112769 JF - Behavioural brain research JO - Behav. Brain Res. VL - 393 N2 - According to preclinical and clinical studies, the antidepressant-induced increase in the activity of atypical antipsychotics may efficiently improve the treatment of negative and some cognitive symptoms of schizophrenia. In the present study, we aimed to evaluate the effects of the antidepressants escitalopram and mirtazapine and the atypical antipsychotic drug aripiprazole, administered separately or in combination, on the MK-801-induced deficits in the recognition memory test and on the extracellular levels of monoamines and their metabolites in the rat frontal cortex. Based on the results of the behavioral tests, co-treatment with an ineffective dose of aripiprazole (0.1 mg/kg) and escitalopram (2.5 and 5 mg/kg) or mirtazapine (5 mg/kg) abolished the deficits evoked by MK-801 in the novel object recognition test, and those effects were blocked by the 5-HT1A receptor antagonist (WAY 100,635) or the dopamine D1 receptor antagonist (SCH 23,390). Moreover, co-treatment with aripiprazole (0.3 mg/kg) and escitalopram (5 mg/kg) significantly increased the levels of noradrenaline and serotonin, decreased the level of its metabolite, and did not alter level of dopamine, but decreased the levels of its metabolites. In addition, co-treatment with aripiprazole (0.3 mg/kg) and mirtazapine (10 mg/kg) significantly increased the level of noradrenaline, did not change the levels of dopamine and serotonin, but increased the levels of their metabolites. Based on these results, the increase in the extracellular levels of noradrenaline or serotonin in the cortex induced by co-treatment with an antidepressant and aripiprazole may be very important for the pharmacotherapy of negative and some cognitive symptoms of schizophrenia. SN - 1872-7549 UR - https://www.unboundmedicine.com/medline/citation/32535184/Effect_of_combined_treatment_with_aripiprazole_and_antidepressants_on_the_MK-801-induced_deficits_in_recognition_memory_in_novel_recognition_test_and_on_the_release_of_monoamines_in_the_rat_frontal_cortex L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-4328(20)30468-X DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.